• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    AeroClean Announces Appointment of Timothy J. Scannell to Board of Directors

    5/12/22 1:00:00 PM ET
    $AERC
    $NVCR
    $PODD
    $RNLX
    Environmental Services
    Utilities
    Medical/Dental Instruments
    Health Care
    Get the next $AERC alert in real time by email

    PALM BEACH GARDENS, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- AeroClean Technologies ("AeroClean" or the "Company") (NASDAQ:AERC), a pathogen elimination technology company harnessing patented UV-C LED technology with Pūrgo™ to significantly reduce and remove harmful pathogens to keep work, play and life going, today announced the appointment of Timothy J. Scannell, former President and Chief Operating Officer at Stryker, to its Board of Directors (the "Board"). On May 11, 2022, the Board appointed Mr. Scannell as a new director on the Board, chair of the Nominating and Corporate Governance Committee and a member of the Compensation Committee.

    Mr. Scannell brings over 30 years of experience and success delivering market-leading results from his leadership roles at Stryker Corporation (NYSE:SYK) ("Stryker"), one of the world's leading medical technology companies. Mr. Scannell served as President and Chief Operating Officer of Stryker between 2018 and 2021, overseeing all of Stryker's commercial businesses and regions globally. Prior to this, he served as group president for Stryker's MedSurg & Neurotechnology businesses for ten years. Mr. Scannell currently serves as a director and non-executive chairman of the Board of Directors for Insulet Corporation (NASDAQ:PODD) and is a director on the boards of Novocure Limited (NASDAQ:NVCR), Renalytix plc (NASDAQ:RNLX) and Collagen Matrix, Inc.

    "Tim Scannell is a medical technology industry veteran with vast experience and a tremendous track record of success. He drove market leading sales and supported Stryker's top tier M&A results during his time at Stryker. He will be a great addition to our Board," said Jason DiBona, AeroClean's Chief Executive Officer. "Tim's interest in joining our Board and helping advance our mission is a testament to our Company's vision. I welcome Tim to the team and look forward to his contributions to the success of AeroClean."

    "I am proud to join the Board of AeroClean. I look forward to supporting and advancing AeroClean's mission of keeping life going with healthy, safe air solutions," said Mr. Scannell. "I am energized by AeroClean's mission, impressed by their board and management team, and enthusiastic about the Company's opportunity to build a great business with tremendous impact on millions of lives in the years to come."

    About AeroClean Technologies

    AeroClean is a pathogen elimination technology company on a mission to keep work, play and life going—with continuous air sanitization products called Pūrgo™ (pure-go). We create solutions for hospitals, offices, and many shared spaces as well as elevators and more. Pūrgo™ products feature SteriDuct™, a proprietary technology developed by our best-in-class aerospace engineers, medical scientists and innovators. Powered by SteriDuct™, our solutions are medical grade, eradicating viral, fungal and bacterial airborne pathogens. Our purpose is simple: to never stop innovating solutions that keep people healthy and safe, so life never stops. Learn more at aeroclean.com.

    Media Contact

    Drew Tybus

    drew@oakpr.com

    Investor Relations Contacts

    Ryan Tyler

    Chief Financial Officer, AeroClean

    RTyler@AeroClean.com

    Brian Pinkston

    MATTIO Communications

    aeroclean@mattio.com



    Primary Logo

    Get the next $AERC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AERC
    $NVCR
    $PODD
    $RNLX

    CompanyDatePrice TargetRatingAnalyst
    NovoCure Limited
    $NVCR
    7/13/2026$17.00Neutral
    Analyst
    Stryker Corporation
    $SYK
    7/9/2026$369.00Outperform
    BMO Capital Markets
    Insulet Corporation
    $PODD
    6/23/2026$190.00Buy
    Deutsche Bank
    Insulet Corporation
    $PODD
    5/20/2026Outperform
    William Blair
    Insulet Corporation
    $PODD
    4/24/2026$220.00Buy → Neutral
    Rothschild & Co Redburn
    Stryker Corporation
    $SYK
    4/13/2026$410.00Outperform
    Leerink Partners
    Insulet Corporation
    $PODD
    4/7/2026$230.00Buy → Neutral
    Citigroup
    Stryker Corporation
    $SYK
    2/20/2026Outperform
    William Blair
    More analyst ratings

    $AERC
    $NVCR
    $PODD
    $RNLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Stonesifer Timothy C. bought $400,393 worth of shares (2,790 units at $143.51), increasing direct ownership by 45% to 9,041 units (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    6/4/26 4:25:37 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Director Weatherman Elizabeth H bought $497,490 worth of shares (3,450 units at $144.20), increasing direct ownership by 50% to 10,352 units (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    6/3/26 4:19:18 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Director Minogue Michael R bought $499,847 worth of shares (2,030 units at $246.23) (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    2/26/26 7:05:23 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $AERC
    $NVCR
    $PODD
    $RNLX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 18, 2024 - FDA Roundup: October 18, 2024

    For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

    10/18/24 4:16:25 PM ET
    $NVCR
    $BAX
    Medical/Dental Instruments
    Health Care

    $AERC
    $NVCR
    $PODD
    $RNLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Huffines Robert Luther was granted 151 shares, increasing direct ownership by 7% to 2,449 units (SEC Form 4)

    4/A - INSULET CORP (0001145197) (Issuer)

    7/7/26 4:41:44 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Director Mazelsky Jonathan Jay was granted 1,355 shares (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    7/2/26 4:12:30 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    New insider Mazelsky Jonathan Jay claimed no ownership of stock in the company (SEC Form 3)

    3 - INSULET CORP (0001145197) (Issuer)

    7/2/26 4:10:28 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $AERC
    $NVCR
    $PODD
    $RNLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analyst resumed coverage on NovoCure with a new price target

    Analyst resumed coverage of NovoCure with a rating of Neutral and set a new price target of $17.00

    7/13/26 9:09:40 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    BMO Capital Markets initiated coverage on Stryker with a new price target

    BMO Capital Markets initiated coverage of Stryker with a rating of Outperform and set a new price target of $369.00

    7/9/26 9:30:57 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    Deutsche Bank initiated coverage on Insulet with a new price target

    Deutsche Bank initiated coverage of Insulet with a rating of Buy and set a new price target of $190.00

    6/23/26 7:56:18 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $AERC
    $NVCR
    $PODD
    $RNLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Stryker expands Mako robotics portfolio with full market release of Mako RPS

    New handheld robotic technology expands the Mako platform and brings Mako robotic-assisted knee replacement to a new segment of the orthopaedic marketStryker announced the U.S. commercial launch of Mako RPS (Robotic Power System) for total knee replacement procedures.The launch introduces Mako Handheld Robotics, expanding the Mako portfolio beyond robotic-arm assisted surgery.Mako RPS combines robotic execution, intraoperative planning and a familiar handheld power tool workflow.PORTAGE, Mich., July 16, 2026 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today the U.S. commercial launch of Mako RPS® (Robotic Power System) for total knee replacement pro

    7/16/26 9:05:00 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    Insulet Partners with Calm to Bring Mindfulness and Well-Being Tools to the Diabetes Community, Featuring a New Sleep Story Narrated by Lila Moss

    The partnership introduces The Mind in Range Collection, a set of tailored mindfulness resources available at no cost to the diabetes community, including a meditation series, a breathing exercise, and a new Calm Sleep Story narrated by Omnipod® user and fashion model Lila Moss, designed to help listeners unwind and feel supported With 359 million people worldwide living with an anxiety disorder1, and people with diabetes being 20% more likely to develop anxiety2, this initiative reinforces Insulet’s commitment to whole-person care and positions mental health as essential to diabetes management The integrated content collaboration is the first-of-its-kind between Calm and a MedTe

    7/14/26 3:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet Accelerates Global Growth with Launch of Omnipod® 5 and Omnipod Discover™ in Spain, Expanding Access to Tubeless Diabetes Technology

    Omnipod 5 Automated Insulin Delivery System now available in 20 countries worldwide New web-based data platform Omnipod Discover simplifies diabetes insights for users, caregivers, and healthcare professionals Omnipod 5 launch in Spain is compatible with Abbott and Dexcom continuous glucose monitoring systems Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the commercial launch of its Omnipod 5 Automated Insulin Delivery System and its proprietary data management system Omnipod Discover™ in Spain, the Company’s newest European market. Spain is the 26th country whe

    7/6/26 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $AERC
    $NVCR
    $PODD
    $RNLX
    SEC Filings

    View All

    NovoCure Limited filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - NovoCure Ltd (0001645113) (Filer)

    6/30/26 7:00:24 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    Stryker Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - STRYKER CORP (0000310764) (Filer)

    6/26/26 3:45:42 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    Insulet Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - INSULET CORP (0001145197) (Filer)

    6/25/26 7:06:41 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $AERC
    $NVCR
    $PODD
    $RNLX
    Financials

    Live finance-specific insights

    View All

    Insulet to Announce Second Quarter 2026 Financial Results on August 5, 2026

    Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the second quarter of 2026 on Wednesday, August 5, 2026, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or

    7/1/26 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Novocure to Report Second Quarter 2026 Financial Results

    Novocure (NASDAQ:NVCR) will report financial results for the second quarter 2026 on July 23, 2026, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, July 23, to discuss the company’s financial results for the three-month period that ended June 30, 2026. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access the webcast, use the following webcast registration link. The slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations page of Novocure’s website, investor.novocure.com, an

    7/1/26 7:00:00 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    Stryker completes acquisition of Amplitude Vascular Systems to add next-generation IVL technology to peripheral vascular portfolio

    Portage, Michigan, May 07, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK announced that it has completed the acquisition of Amplitude Vascular Systems, Inc. (AVS), a privately held medical technology company developing a next-generation intravascular lithotripsy (IVL) platform designed to treat complex peripheral arterial disease. "This acquisition is a significant milestone in expanding our peripheral vascular portfolio and enhancing our ability to address challenging arterial disease," said Kevin Lobo, Chair and CEO, Stryker. "By integrating AVS's innovative CO₂-generated pressure wave technology with Stryker's scale and resources, we are well-positioned to deliver solutions that support p

    5/7/26 4:05:00 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    $AERC
    $NVCR
    $PODD
    $RNLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Insulet Corporation

    SC 13G/A - INSULET CORP (0001145197) (Subject)

    11/12/24 12:53:28 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Insulet Corporation

    SC 13G/A - INSULET CORP (0001145197) (Subject)

    10/7/24 11:37:08 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Renalytix plc

    SC 13D/A - Renalytix plc (0001811115) (Subject)

    10/2/24 8:05:02 PM ET
    $RNLX
    Medical Specialities
    Health Care

    $AERC
    $NVCR
    $PODD
    $RNLX
    Leadership Updates

    Live Leadership Updates

    View All

    Insulet Announces Appointment of Jonathan J. Mazelsky to its Board of Directors

    Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the appointment of Jonathan ("Jay") Mazelsky to the Company’s Board of Directors, effective July 1, 2026. Mr. Mazelsky joins the Board as an independent director. "We are pleased to welcome Jay to Insulet’s Board of Directors," said President and CEO Ashley McEvoy. "Jay has a strong track record of translating science into solutions to drive growth and create significant and enduring shareholder value. His background and expertise will be integral as Insulet continues to expand access and further strengthen Omnipod’s leaders

    6/25/26 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet Appoints Mike Panos as Chief Commercial Officer

    Insulet Corporation (NASDAQ:PODD) ("Insulet" or the "Company"), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the appointment of Mike Panos as Executive Vice President, Chief Commercial Officer, effective immediately. In this role, Mr. Panos will lead Insulet's global commercial organization, reporting to President and Chief Executive Officer Ashley McEvoy. He will also be a member of the Executive Leadership Team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330524787/en/ "We have a significant growth opportunity in front of us, driven by strong clinical outcomes

    3/30/26 8:30:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    GE HealthCare appoints medtech leader Kevin Lobo to Board of Directors

    GE HealthCare (NASDAQ:GEHC) announced today the appointment of Kevin A. Lobo, Chair and Chief Executive Officer of Stryker Corporation (NYSE:SYK), to its Board of Directors effective March 13. Mr. Lobo brings more than 25 years of medical technology, operational, and financial leadership experience. His clinical expertise and track record of driving innovation and scaling global businesses make him well qualified to contribute to GE HealthCare's strategic priorities. "Kevin is a seasoned healthcare executive with a deep understanding of the medical technology landscape. His knowledge and insight will further strengthen our Board as we continue to build a more personalized, connected and s

    3/17/26 9:00:00 AM ET
    $GEHC
    $SYK
    Medical Electronics
    Health Care
    Medical/Dental Instruments